Mesoblast (MESO) Stock Forecast & Price Target $14.52 -0.03 (-0.21%) Closing price 04:00 PM EasternExtended Trading$14.36 -0.15 (-1.07%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Mesoblast - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 3 Analyst RatingsSell1Hold1Buy1 Based on 3 Wall Street analysts who have issued ratings for Mesoblast in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a strong buy rating for MESO. Consensus Price Target N/A MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for MESO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Mesoblast and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MESO Analyst Ratings Over TimeTypeCurrent Forecast5/20/25 to 5/20/261 Month Ago4/20/25 to 4/20/263 Months Ago2/19/25 to 2/19/261 Year Ago5/20/24 to 5/20/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)2 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price TargetN/AN/AN/A$18.00Forecasted UpsideN/AN/AN/A55.98% UpsideConsensus RatingHoldHoldModerate BuyBuy MESO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MESO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Mesoblast Stock vs. The CompetitionTypeMesoblastMedical CompaniesBroader MarketConsensus Rating Score 2.33 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted UpsideN/A1,742.56% Upside17.78% UpsideNews Sentiment RatingNeutral NewsSee Recent MESO NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails4/21/2026 Weiss RatingsNot Rated Reiterated RatingSell (E+)8/5/2025 Canaccord Genuity Group4 of 5 stars UpgradeStrong-Buy7/18/2025 Jefferies Financial Group2 of 5 starsDavid StantonNot RatedDowngradeBuy ➝ Hold3/31/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingOlivia BrayerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy2/7/2025 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEdward TenthoffSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight$15.00 ➝ $24.00+20.94%9/24/2024 Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael OkunewitchSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy$12.00+78.04%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:12 PM ET. MESO Forecast - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last twelve months. There is currently 1 sell rating, 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. Does Mesoblast's stock price have much downside? According to analysts, Mesoblast's stock has a predicted downside of -100.00% based on their 12-month stock forecasts. What analysts cover Mesoblast? Mesoblast has been rated by research analysts at Weiss Ratings in the past 90 days. Do Wall Street analysts like Mesoblast more than its competitors? Analysts like Mesoblast more than other "medical" companies. The consensus rating score for Mesoblast is 2.33 while the average consensus rating score for "medical" companies is 2.29. Learn more on how MESO compares to other companies. Stock Forecasts and Research Tools Related Companies Kymera Therapeutics Stock Forecast Qiagen Stock Forecast TG Therapeutics Stock Forecast Mirum Pharmaceuticals Stock Forecast Spyre Therapeutics Stock Forecast Rhythm Pharmaceuticals Stock Forecast Protagonist Therapeutics Stock Forecast Belite Bio Stock Forecast CG Oncology Stock Forecast Terns Pharmaceuticals Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Mesoblast RecommendationsWeiss RatingsCanaccord Genuity GroupJefferies Financial Group This page (NASDAQ:MESO) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
